Global Basaglar Sales Track Towards $1bn Per Year
Global sales of Eli Lilly's Basaglar insulin glargine hybrid are on track to surpass $1bn per year
You may also be interested in...
Mylan has moved up to become the world’s leading generics, biosimilars and OTC player, according to Generics Bulletin’s newly compiled global rankings. Sandoz has surpassed troubled Teva into second spot, but is set to surrender that position once it sells its US solid-dose and dermatology business to India’s Aurobindo, which has already moved into the global top 10.
Eli Lilly has launched its authorized generic of its own Humalog (insulin lispro) brand in the US, at a 50% discount to the list price of the original.
Germany’s off-patent industry association, Pro Generika, is finding ample support for its position that by awarding tender contracts to exclusive suppliers, health insurance funds are contributing to drug shortages in the country.